NASH肝硬化腹水失代偿后结局较HBV肝硬化更差
一项回顾性研究比较NASH与HBV肝硬化患者首次腹水入院后的结局,随访至死亡、肝移植或失访。NASH组MELD评分较低,但5年内稀释性低钠血症、难治性腹水及肝硬化相关死亡/肝移植累积发生率更高,NASH为不良无移植生存的独立预测因素。
要点
- NASH肝硬化腹水失代偿后肝硬化相关死亡/肝移植风险显著高于HBV肝硬化。
- NASH组稀释性低钠血症和难治性腹水累积发生率更高。
- NASH、非华裔、HCC史、eGFR<60及MELD≥15为不良无移植生存独立预测因素。
核心结论
- NASH所致肝硬化腹水失代偿后预后较HBV肝硬化更差,并发症更多且医疗资源利用更高。
研究设计与样本
- 回顾性研究纳入2004年1月1日至2015年6月30日因首次腹水入院NASH和HBV肝硬化患者,随访至死亡、肝移植或失访。
主要发现
- NASH组中位MELD评分为11(9-14),低于HBV组的14(11-17),P<0.001。
- 60个月内NASH组稀释性低钠血症累积发生率更高(P<0.001),难治性腹水累积发生率更高(P=0.028)。
- NASH组肝硬化相关死亡和肝移植累积发生率为65.7%(95%CI 53.6-75.4),高于HBV组的42.5%(95%CI 32.4-55.2),P=0.008。
- 多变量竞争风险分析显示NASH(sHR 1.88,95%CI 1.14-3.11,P=0.014)、非华裔(sHR 1.63,95%CI 1.06-2.50,P=0.027)、HCC史(sHR 1.76,95%CI 1.05-2.95,P=0.033)、eGFR<60 mL/min/1.73 m2(sHR 1.70,95%CI 1.09-2.65,P=0.020)及MELD≥15(sHR 3.26,95%CI 2.11-5.05,P<0.001)为不良无移植生存独立预测因素。
临床怎么用
- 对NASH肝硬化患者应提高警惕,在失代偿前尽早诊断并加强管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Decompensation with ascites portends a poor prognosis in cirrhosis. The aim of this study was to compare the outcomes of patients with nonalcoholic steatohepatitis (NASH) with hepatitis B virus (HBV) cirrhosis after decompensation with ascites. METHODS: We conducted a retrospective study to evaluate the outcomes of patients with NASH and HBV cirrhosis who were admitted to hospital for first-onset ascites from January 1, 2004, to June 30, 2015. They were followed up until death, liver transplantation, or loss to follow up. RESULTS: Patients with NASH had lower median (interquartile range) Model for End-Stage Liver Disease score (11 [9-14] vs 14 [11-17], P < 0.001). Over 60 months, patients with NASH cirrhosis had higher cumulative incidence of dilutional hyponatremia (P < 0.001) and refractory ascites (P = 0.028). They also had higher cumulative incidence of cirrhosis-related deaths and liver transplantation compared with HBV cirrhosis (65.7%; [95% confidence interval (CI) 53.6-75.4] vs 42.5% [95% CI 32.4-55.2], P = 0.008). Multivariable competing risk analysis showed that NASH (subdistribution hazard ratio [sHR] 1.88 [95% CI 1.14-3.11], P = 0.014), non-Chinese ethnicity (sHR 1.63 [95% CI 1.06-2.50], P = 0.027), history of hepatocellular carcinoma (sHR 1.76 [95% CI 1.05-2.95], P = 0.033), estimated glomerular filtration rate <60 mL/min/1.73 m2 (sHR 1.70 [95% CI 1.09-2.65], P = 0.020), and Model for End-Stage Liver Disease score ≥15 (sHR 3.26 [95% CI 2.11-5.05], P < 0.001) were independent predictors of poor transplant-free survival. DISCUSSION: Patients with decompensated cirrhosis due to NASH had much poorer prognosis compared with HBV with more complications and greater healthcare resource utilization. Greater awareness is necessary for early diagnosis of NASH before decompensation.
引用
- Tan HK, Teng MLP, Soh AYS, et al. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites. Am J Gastroenterol. 2021. PMID: 33834737. doi:10.14309/ajg.0000000000001176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。